;PMID: 9600124
;source_file_679.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:45..131] = [t:45..131]
;2)section:[e:135..244] = [t:135..244]
;3)section:[e:248..323] = [t:248..323]
;4)sentence:[e:327..425] = [t:327..425]
;5)sentence:[e:426..544] = [t:426..544]
;6)sentence:[e:545..837] = [t:545..837]
;7)sentence:[e:838..971] = [t:838..971]
;8)sentence:[e:972..1100] = [t:972..1100]
;9)sentence:[e:1101..1159] = [t:1101..1159]
;10)sentence:[e:1160..1240] = [t:1160..1240]
;11)section:[e:1244..1288] = [t:1244..1288]

;section 0 Span:0..40
;Jpn J Cancer Res  1998 Mar;89(3):299-306
(SEC
  (FRAG (NNP:[0..3] Jpn) (NNP:[4..5] J) (NNP:[6..12] Cancer) (NNP:[13..16] Res)
        (CD:[18..22] 1998) (CC:[23..30] Mar;89-LRB-) (CD:[30..31] 3)
        (-RRB-:[31..32] -RRB-) (CD:[32..36] :299) (::[36..37] -)
        (CD:[37..40] 306)))

;sentence 1 Span:45..131
;Genetic alterations of mixed hyperplastic adenomatous polyps in the colon and
; rectum.
;[68..118]:malignancy:"mixed hyperplastic adenomatous polyps in the colon"
;[68..112]...[124..130]:malignancy:"mixed hyperplastic adenomatous polyps in
;the"..."rectum"
(SENT
  (NP-HLN
    (NP (JJ:[45..52] Genetic) (NNS:[53..64] alterations))
    (PP (IN:[65..67] of)
      (NP (JJ:[68..73] mixed) (JJ:[74..86] hyperplastic)
          (JJ:[87..98] adenomatous) (NNS:[99..105] polyps)))
    (PP-LOC (IN:[106..108] in)
      (NP (DT:[109..112] the) (NN:[113..118] colon) (CC:[119..122] and)
          (NN:[124..130] rectum)))
    (.:[130..131] .)))

;section 2 Span:135..244
;Uchida H, Ando H, Maruyama K, Kobayashi H, Toda H, Ogawa H, Ozawa T, Matsuda
;Y,  Sugimura H, Kanno T, Baba S.
(SEC
  (FRAG (NNP:[135..141] Uchida) (NNP:[142..143] H) (,:[143..144] ,)
        (NNP:[145..149] Ando) (NNP:[150..151] H) (,:[151..152] ,)
        (NNP:[153..161] Maruyama) (NNP:[162..163] K) (,:[163..164] ,)
        (NNP:[165..174] Kobayashi) (NNP:[175..176] H) (,:[176..177] ,)
        (NNP:[178..182] Toda) (NNP:[183..184] H) (,:[184..185] ,)
        (NNP:[186..191] Ogawa) (NNP:[192..193] H) (,:[193..194] ,)
        (NNP:[195..200] Ozawa) (NNP:[201..202] T) (,:[202..203] ,)
        (NNP:[204..211] Matsuda) (NNP:[212..213] Y) (,:[213..214] ,)
        (NNP:[216..224] Sugimura) (NNP:[225..226] H) (,:[226..227] ,)
        (NNP:[228..233] Kanno) (NNP:[234..235] T) (,:[235..236] ,)
        (NNP:[237..241] Baba) (NNP:[242..244] S.)))

;section 3 Span:248..323
;Department of Laboratory Medicine, Hamamatsu University School of Medicine.
(SEC
  (FRAG (NNP:[248..258] Department) (IN:[259..261] of)
        (NNP:[262..272] Laboratory) (NNP:[273..281] Medicine) (,:[281..282] ,)
        (NNP:[283..292] Hamamatsu) (NNP:[293..303] University)
        (NNP:[304..310] School) (IN:[311..313] of) (NNP:[314..322] Medicine)
        (.:[322..323] .)))

;sentence 4 Span:327..425
;Some mixed hyperplastic adenomatous polyps (MHAPs) contain dysplastic lesions
;or  even carcinomas.
;[332..369]:malignancy:"mixed hyperplastic adenomatous polyps"
;[371..376]:malignancy:"MHAPs"
;[386..404]:malignancy:"dysplastic lesions"
;[414..424]:malignancy:"carcinomas"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[327..331] Some)
         (JJ:[332..337] mixed) (JJ:[338..350] hyperplastic)
         (JJ:[351..362] adenomatous) (NNS:[363..369] polyps))
      (NP (-LRB-:[370..371] -LRB-) (NNS:[371..376] MHAPs)
          (-RRB-:[376..377] -RRB-)))
    (VP (VBP:[378..385] contain)
      (NP
        (NP (JJ:[386..396] dysplastic) (NNS:[397..404] lesions))
        (CC:[405..407] or)
        (NP (RB:[409..413] even) (NNS:[414..424] carcinomas))))
    (.:[424..425] .)))

;sentence 5 Span:426..544
;These polyps are considered to be different from ordinary  hyperplastic
;polyps and may have a preneoplastic potential.
;[432..438]:malignancy:"polyps"
;[485..504]:malignancy:"hyperplastic polyps"
(SENT
  (S
    (NP-SBJ-1 (DT:[426..431] These) (NNS:[432..438] polyps))
    (VP
      (VP (VBP:[439..442] are)
        (VP (VBN:[443..453] considered)
          (S
            (NP-SBJ-1 (-NONE-:[453..453] *))
            (VP (TO:[454..456] to)
              (VP (VB:[457..459] be)
                (ADJP-PRD (JJ:[460..469] different)
                  (PP (IN:[470..474] from)
                    (NP (JJ:[475..483] ordinary)
                       (JJ:[485..497] hyperplastic) (NNS:[498..504] polyps)))))))))
      (CC:[505..508] and)
      (VP (MD:[509..512] may)
        (VP (VB:[513..517] have)
          (NP (DT:[518..519] a) (JJ:[520..533] preneoplastic)
              (NN:[534..543] potential)))))
    (.:[543..544] .)))

;sentence 6 Span:545..837
;We investigated APC  and K-ras mutations in MHAPs of the colon and rectum,
;and also in colorectal  adenomas and hyperplastic polyps to identify
;molecular differences between  MHAPs, adenomas and hyperplastic polyps, using
;direct sequencing of mutation  cluster regions (MCR) in APC and K-ras.
;[561..564]:gene-rna:"APC"
;[570..575]:gene-rna:"K-ras"
;[589..607]:malignancy:"MHAPs of the colon"
;[589..601]...[612..618]:malignancy:"MHAPs of the"..."rectum"
;[632..652]:malignancy:"colorectal  adenomas"
;[657..676]:malignancy:"hyperplastic polyps"
;[720..725]:malignancy:"MHAPs"
;[727..735]:malignancy:"adenomas"
;[740..759]:malignancy:"hyperplastic polyps"
;[823..826]:gene-rna:"APC"
;[831..836]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ (PRP:[545..547] We))
    (VP (VBD:[548..560] investigated)
      (NP
        (NP
          (NP (NN:[561..564] APC)
            (NML-1 (-NONE-:[564..564] *P*)))
          (CC:[566..569] and)
          (NP (NN:[570..575] K-ras)
            (NML-1 (NNS:[576..585] mutations))))
        (PP-LOC
          (PP (IN:[586..588] in)
            (NP
              (NP (NNS:[589..594] MHAPs))
              (PP (IN:[595..597] of)
                (NP (DT:[598..601] the) (NN:[602..607] colon)
                    (CC:[608..611] and) (NN:[612..618] rectum)))))
          (,:[618..619] ,)
          (CONJP (CC:[620..623] and) (RB:[624..628] also))
          (PP (IN:[629..631] in)
            (NP
              (NP (JJ:[632..642] colorectal) (NNS:[644..652] adenomas))
              (CC:[653..656] and)
              (NP (JJ:[657..669] hyperplastic) (NNS:[670..676] polyps))))))
      (S-PRP
        (NP-SBJ (-NONE-:[676..676] *))
        (VP (TO:[677..679] to)
          (VP (VB:[680..688] identify)
            (NP
              (NP (JJ:[689..698] molecular) (NNS:[699..710] differences))
              (PP (IN:[711..718] between)
                (NP
                  (NP (NNS:[720..725] MHAPs))
                  (,:[725..726] ,)
                  (NP (NNS:[727..735] adenomas))
                  (CC:[736..739] and)
                  (NP (JJ:[740..752] hyperplastic) (NNS:[753..759] polyps))))))))
      (,:[759..760] ,)
      (S-MNR
        (NP-SBJ (-NONE-:[760..760] *))
        (VP (VBG:[761..766] using)
          (NP
            (NP (JJ:[767..773] direct) (NN:[774..784] sequencing))
            (PP (IN:[785..787] of)
              (NP
                (NP
                  (NP (NN:[788..796] mutation) (NN:[798..805] cluster)
                      (NNS:[806..813] regions))
                  (NP (-LRB-:[814..815] -LRB-) (NN:[815..818] MCR)
                      (-RRB-:[818..819] -RRB-)))
                (PP-LOC (IN:[820..822] in)
                  (NP
                    (NP (NN:[823..826] APC))
                    (CC:[827..830] and)
                    (NP (NN:[831..836] K-ras))))))))))
    (.:[836..837] .)))

;sentence 7 Span:838..971
;No APC mutations were identified in 12  MHAPs and 8 hyperplastic polyps,
;whereas 10 of 27 (37.0%) adenomas showed  somatic mutations.
;[841..844]:gene-rna:"APC"
;[878..883]:malignancy:"MHAPs"
;[890..909]:malignancy:"hyperplastic polyps"
;[936..944]:malignancy:"adenomas"
(SENT
  (S
    (NP-SBJ-1 (DT:[838..840] No) (NN:[841..844] APC) (NNS:[845..854] mutations))
    (VP (VBD:[855..859] were)
      (VP (VBN:[860..870] identified)
        (NP-1 (-NONE-:[870..870] *))
        (PP-LOC (IN:[871..873] in)
          (NP
            (NP (CD:[874..876] 12) (NNS:[878..883] MHAPs))
            (CC:[884..887] and)
            (NP (CD:[888..889] 8)
               (JJ:[890..902] hyperplastic) (NNS:[903..909] polyps))))
        (,:[909..910] ,)
        (SBAR-ADV (IN:[911..918] whereas)
          (S
            (NP-SBJ
              (NP (CD:[919..921] 10))
              (PP (IN:[922..924] of)
                (NP (CD:[925..927] 27)
                  (PRN (-LRB-:[928..929] -LRB-)
                    (NP (CD:[929..933] 37.0) (NN:[933..934] %))
                    (-RRB-:[934..935] -RRB-))
                  (NNS:[936..944] adenomas))))
            (VP (VBD:[945..951] showed)
              (NP (JJ:[953..960] somatic) (NNS:[961..970] mutations)))))))
    (.:[970..971] .)))

;sentence 8 Span:972..1100
;K-ras mutations were identified in one of 12 (8.3%) MHAPs,  one of 8 (12.5%)
;hyperplastic polyps, and 10 of 27 (37.0%) adenomas.
;[972..977]:gene-rna:"K-ras"
;[1024..1029]:malignancy:"MHAPs"
;[1049..1068]:malignancy:"hyperplastic polyps"
;[1091..1099]:malignancy:"adenomas"
(SENT
  (S
    (NP-SBJ-1 (NN:[972..977] K-ras) (NNS:[978..987] mutations))
    (VP (VBD:[988..992] were)
      (VP (VBN:[993..1003] identified)
        (NP-1 (-NONE-:[1003..1003] *))
        (PP (IN:[1004..1006] in)
          (NP
            (NP
              (NP (CD:[1007..1010] one))
              (PP (IN:[1011..1013] of)
                (NP (CD:[1014..1016] 12)
                  (PRN (-LRB-:[1017..1018] -LRB-)
                    (NP (CD:[1018..1021] 8.3) (NN:[1021..1022] %))
                    (-RRB-:[1022..1023] -RRB-))
                  (NNS:[1024..1029] MHAPs))))
            (,:[1029..1030] ,)
            (NP
              (NP (CD:[1032..1035] one))
              (PP (IN:[1036..1038] of)
                (NP (CD:[1039..1040] 8)
                  (PRN (-LRB-:[1041..1042] -LRB-)
                    (NP (CD:[1042..1046] 12.5) (NN:[1046..1047] %))
                    (-RRB-:[1047..1048] -RRB-))
                   (JJ:[1049..1061] hyperplastic) (NNS:[1062..1068] polyps))))
            (,:[1068..1069] ,) (CC:[1070..1073] and)
            (NP
              (NP (CD:[1074..1076] 10))
              (PP (IN:[1077..1079] of)
                (NP (CD:[1080..1082] 27)
                  (PRN (-LRB-:[1083..1084] -LRB-)
                    (NP (CD:[1084..1088] 37.0) (NN:[1088..1089] %))
                    (-RRB-:[1089..1090] -RRB-))
                  (NNS:[1091..1099] adenomas))))))))
    (.:[1099..1100] .)))

;sentence 9 Span:1101..1159
;p53  mutation was found in a carcinoma arising in an MHAP.
;[1101..1104]:gene-rna:"p53"
;[1130..1139]:malignancy:"carcinoma"
;[1154..1158]:malignancy:"MHAP"
(SENT
  (S
    (NP-SBJ-1 (NN:[1101..1104] p53) (NN:[1106..1114] mutation))
    (VP (VBD:[1115..1118] was)
      (VP (VBN:[1119..1124] found)
        (NP-1 (-NONE-:[1124..1124] *))
        (PP-LOC (IN:[1125..1127] in)
          (NP
            (NP (DT:[1128..1129] a) (NN:[1130..1139] carcinoma))
            (VP (VBG:[1140..1147] arising)
              (PP-LOC (IN:[1148..1150] in)
                (NP (DT:[1151..1153] an) (NN:[1154..1158] MHAP))))))))
    (.:[1158..1159] .)))

;sentence 10 Span:1160..1240
;Mutations other than APC  mutations may play a role in the development of
;MHAPs.
;[1181..1184]:gene-rna:"APC"
;[1234..1239]:malignancy:"MHAPs"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1160..1169] Mutations))
      (ADJP (JJ:[1170..1175] other)
        (PP (IN:[1176..1180] than)
          (NP (NN:[1181..1184] APC) (NNS:[1186..1195] mutations)))))
    (VP (MD:[1196..1199] may)
      (VP (VB:[1200..1204] play)
        (NP (DT:[1205..1206] a) (NN:[1207..1211] role))
        (PP (IN:[1212..1214] in)
          (NP
            (NP (DT:[1215..1218] the) (NN:[1219..1230] development))
            (PP (IN:[1231..1233] of)
              (NP (NNS:[1234..1239] MHAPs)))))))
    (.:[1239..1240] .)))

;section 11 Span:1244..1288
;PMID: 9600124 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1244..1248] PMID) (::[1248..1249] :) (CD:[1250..1257] 9600124)
        (NN:[1258..1259] -LSB-) (NNP:[1259..1265] PubMed) (::[1266..1267] -)
        (NN:[1268..1275] indexed) (IN:[1276..1279] for)
        (NNP:[1280..1288] MEDLINE-RSB-)))
